Orexigen Therapeutics (NASDAQ:OREX) was upgraded by equities researchers at ValuEngine from a “strong sell” rating to a “sell” rating in a report released on Friday.
Separately, Zacks Investment Research raised shares of Orexigen Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, January 16th.
Shares of Orexigen Therapeutics (OREX) remained flat at $$1.08 during mid-day trading on Friday. 229,807 shares of the company’s stock traded hands, compared to its average volume of 249,678. Orexigen Therapeutics has a 1-year low of $1.05 and a 1-year high of $5.70. The company has a quick ratio of 1.71, a current ratio of 2.00 and a debt-to-equity ratio of -2.75.
An institutional investor recently raised its position in Orexigen Therapeutics stock. Wells Fargo & Company MN boosted its position in shares of Orexigen Therapeutics, Inc. (NASDAQ:OREX) by 2.5% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 45,638 shares of the biopharmaceutical company’s stock after purchasing an additional 1,100 shares during the period. Wells Fargo & Company MN owned approximately 0.30% of Orexigen Therapeutics worth $132,000 at the end of the most recent reporting period. Institutional investors own 34.57% of the company’s stock.
WARNING: “Orexigen Therapeutics (OREX) Lifted to “Sell” at ValuEngine” was first posted by American Banking News and is owned by of American Banking News. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2018/02/04/orexigen-therapeutics-orex-lifted-to-sell-at-valuengine.html.
Orexigen Therapeutics Company Profile
Orexigen Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the treatment of obesity. The Company’s product, Contrave, is approved in the United States by the United States Food and Drug Administration as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kilograms per square meter or greater (obese) or 27 kilograms per square meter or greater (overweight) in the presence of a weight-related comorbid condition.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Orexigen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orexigen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.